Orexigen Raises $30 Million

Orexigen Therapeutics Inc., a San Diego-based neuroscience company focused on the treatment of obesity, has raised $30 million in Series C funding. MPM BioEquities and Wasatch Advisors co-led the deal, and were joined by undisclosed return backers. The company previously had raised over $46 million, including a $35 million Series B deal in April 2005 at a $75 million post-money valuation. Participants in that round included BA Venture Partners, Domain Associates, Duke University, Kleiner Perkins Caufield & Byers, Montreaux Equity Partners, Morgenthaler Ventures and Sofinnova Ventures. www.orexigen.com